Increasing unusual call option volume: ALXN RFP
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Tech stocks bolster Wall Street as Nvidia quells AI growth concerns
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil rises by over $1 as White House says no US-Iran talks happening
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
- First Financial to acquire Hickory Point Bank in $111.3M deal
Alexion Pharmaceuticals (ALXN) PT Raised to $156 at Nomura/Instinet
March 15, 2018 1:45 PM EDTNomura/Instinet raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $156.00 (from $148.00) while maintaining a Buy rating.
Analyst Christopher Marai commented, "Alexion reported results from the P3 301 study of ALXN1210 in PNH-naïve patients. The study demonstrated non-inferiority across all co-primary and four key... More
Alexion Pharmaceuticals (ALXN) PT Raised to $160 at Baird
March 15, 2018 12:14 PM EDTBaird raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $160.00 (from $150.00) while maintaining a Outperform rating.
Analyst Michael E. Ulz commented, "Following the call, we remain encouraged by the Phase 3 PNH naïve results with ALXN1210 demonstrating non-inferiority on all six key endpoints with... More
